FDA Approves Vidaza for Myelodysplastic Syndromes (MDS)
Vidaza is an anticancer drug indicated for the treatment of Myelodysplastic Syndromes (MDS).Posted: May 2004
Related articles
- Vidaza Receives Expanded FDA Approval to Include Overall Survival in Higher-Risk MDS - August 21, 2008
- Pharmion Corporation Announces FDA Approval of Vidaza NDASupplement for IV Administration - January 30, 2007
- FDA Accepts Pharmion's New Drug Application for Filing and Grants Priority Review for Vidaza for the Treatment of Myelodysplastic Syndromes (MDS) - February 23, 2004
Vidaza (azacitidine) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
